ANDA Approvals In 2002 Could Affect Over $10 Bil. In Brand Sales
Executive Summary
Branded products representing more than $10 bil. in annual sales are vulnerable to first generic competition in 2002
You may also be interested in...
GSK Sees New Round Of “Defensive Mergers” Ahead, CEO Says
GlaxoSmithKline sees another round of defensive mergers coming in the pharmaceutical industry, CEO J.P. Garnier declared during a securities analysts meeting in London Feb. 14
GSK Sees New Round Of “Defensive Mergers” Ahead, CEO Says
GlaxoSmithKline sees another round of defensive mergers coming in the pharmaceutical industry, CEO J.P. Garnier declared during a securities analysts meeting in London Feb. 14
Schering Nasonex patents
Schering-Plough has a patent (no. 6,127,353) on mometasone furoate monohydrate, the active ingredient in the nasal inhaler Nasonex, that runs until 2018 (including a pediatric extension). The basic patent on mometasone furoate (no. 4,472,393) expires in March 2002. Both patents are listed in the FDA "Orange Book" for Nasonex (1"The Pink Sheet" Jan. 14, p. 8)...